SPOTLIGHT -
Dr. Katz on Redefining Risk Stratification in Prostate Cancer
Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.
Read More
Dr. Katz on the Oncotype DX GPS Assay in Prostate Cancer
Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.
Dr. Katz on Redefining Risk Assessment in Prostate Cancer With 17-Gene Oncotype DX GPS
Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.
Dr. Katz on Determining Low-Risk Disease in Prostate Cancer
Aaron E. Katz, MD, FACS, discusses strategies for determining low-risk prostate cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
